Discusses new requirement for private insurers to cover PrEP without cost-sharing, an early analysis of insurer compliance, and the need for federal and state enforcement.
Provides details on how insurers’ treatment of manufacturer copay assistance affects patients’ out-of-pocket spending and how high costs drive up prescription abandonment rates, especially while patients deal with the economic effects of COVID.
Provides an update on the growing practice by insurance company and PBMs that do not count copay assistance for prescription drugs towards a beneficiary’s deductible and out-of-pocket spending limits. Discusses the impact on patients and what it is being done at the state and federal levels to stop this practice.